Literature DB >> 31494533

Role of ghrelin on growth hormone/insulin-like growth factor-1 axis during endotoxemia.

Felipe Faim1, Patricia Passaglia2, Marcelo Batalhao3, Riccardo Lacchini4, Angelita Maria Stabile5, Evelin Capellari Carnio6.   

Abstract

OBJECTIVE: To investigate the anti-inflammatory property of ghrelin treatment on the Growth Hormone (GH)/Insulin-like Growth Factor-I (IGF-1) axis in Wistar rats that have undergone endotoxemia.
DESIGN: In this randomized animal study, lipopolysaccharide (LPS) (5 mg/kg; intraperitoneal) was administered to induce endotoxemia, and ghrelin (15 nmol/kg; endovenous) was injected simultaneously. Blood and liver samples were collected 2 h, 6 h and 12 h after LPS administration for analysis. MEASUREMENTS: Tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, beta (IL-1β), and IL-6 from both blood and liver were determined by ELISA assay. Serum nitrate was determined by chemiluminescense. Growth hormone receptor (GHR) and growth hormone secretagogue receptor 1a (GHSR-1a) were determined by western blotting. GHR mRNA and IGF-1 mRNA were determined by RT-PCR.
RESULTS: LPS administration induced a decrease in IGF-1 and GH serum levels, characterizing GH/IGF-1 axis disruption. Ghrelin treatment attenuated the decrease of serum levels of IGF-1 as well as the increase of TNF-α, IL-1β, IL-6 and nitrate induced by LPS. The increase of induced GHSR-1a protein expression seen in the LPS group after 2 h remained until 6 h after ghrelin treatment. However, attenuation of the circulating IGF-1 decrease by ghrelin treatment was not accompanied by changes in GHR protein expression nor GHR and IGF-1 gene expression.
CONCLUSION: Ghrelin was able to attenuate changes in the GH/IGF-1 axis observed during systemic inflammation, which may be due to the modulation of pro-inflammatory mediators release.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; GH; Ghrelin; Growth hormone; IGF-1; Inflammation; Insulin-like growth factor; LPS; Lipopolysaccharide; Sepsis

Mesh:

Substances:

Year:  2019        PMID: 31494533     DOI: 10.1016/j.ghir.2019.08.004

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  5 in total

1.  Ghrelin Alleviates Intestinal Dysfunction in Sepsis Through the KLF4/MMP2 Regulatory Axis by Activating SIRT1.

Authors:  Bin Li; Zhimin Dou; Lei Zhang; Lei Zhu; Yongqiang Cao; Qin Yu
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

Review 2.  Ghrelin as an Anti-Sepsis Peptide: Review.

Authors:  Nimisha Mathur; Syed F Mehdi; Manasa Anipindi; Monowar Aziz; Sawleha A Khan; Hema Kondakindi; Barbara Lowell; Ping Wang; Jesse Roth
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

3.  Central Administration of Angiotensin-(1-7) Improves Vasopressin Impairment and Hypotensive Response in Experimental Endotoxemia.

Authors:  Patrícia Passaglia; Felipe de Lima Faim; Marcelo Eduardo Batalhão; Angelita Maria Stabile; Lusiane Maria Bendhack; José Antunes-Rodrigues; Riccardo Lacchini; Evelin Capellari Carnio
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

4.  The role of environmental enteric dysfunction in the pathogenesis of Schistosoma mansoni-associated morbidity in school-aged children.

Authors:  Jacqueline Araújo Fiuza; Susannah Colt; Letícia Gambogi de Ornellas; Leonardo Ferreira Matoso; Andrea Gazzinelli; Jennifer F Friedman; Rodrigo Corrêa-Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2022-10-05

Review 5.  Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.

Authors:  Jean-Marc Cavaillon; Mervyn Singer; Tomasz Skirecki
Journal:  EMBO Mol Med       Date:  2020-03-16       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.